+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuroprotection Market - Global Forecast 2026-2032- Product Image
Neuroprotection Market - Global Forecast 2026-2032- Product Image
Sale

Neuroprotection Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4857892
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neuroprotection Market is projected to reach USD 37.01 Billion in 2026. It is expected to continue growing at a CAGR of 7.93%, reaching USD 58.74 Billion by 2032.

Neuroprotection is moving from a largely experimental concept to a strategic healthcare priority as neurological disorders place rising pressure on health systems, biopharmaceutical pipelines, and long-term care budgets. The World Health Organization reports that more than 55 million people live with dementia worldwide, while stroke remains a leading cause of death and disability. Parkinson’s disease affected more than 8.5 million people in 2019, and multiple sclerosis affects an estimated 2.8 million people globally, reinforcing the scale of unmet need across acute and chronic neurodegenerative conditions.

The neuroprotection market includes disease-modifying drugs, biologics, cell and gene therapies, mitochondrial and anti-inflammatory approaches, digital biomarkers, neuromonitoring tools, and supportive technologies designed to preserve neuronal structure and function. Demand is strongest where aging populations, improved diagnostic capacity, stroke systems of care, and advanced neuroscience research converge. For industry leaders, the opportunity is no longer limited to symptom control; it is increasingly defined by measurable slowing of neuronal injury, earlier intervention, and evidence-based patient stratification.

Transformative Shifts in the Neuroprotection Landscape

The neuroprotection landscape is being reshaped by the shift from broad neuroprotective claims toward mechanism-specific, biomarker-guided therapies. Clinical development is increasingly focused on inflammation, excitotoxicity, oxidative stress, proteostasis, synaptic resilience, vascular injury, and mitochondrial dysfunction. This change is important because past neuroprotection trials frequently failed when heterogeneous patient populations, delayed treatment windows, or insensitive endpoints diluted measurable benefit.

Regulatory and clinical momentum is also changing expectations. The U.S. FDA’s accelerated approval pathway for anti-amyloid therapies in Alzheimer’s disease and subsequent confirmatory requirements have reinforced the role of biomarkers, real-world safety monitoring, and clinically meaningful outcomes. In stroke and traumatic brain injury, improved imaging, thrombectomy systems, and critical care protocols are creating more precise opportunities for adjunctive neuroprotective interventions. Across the sector, success increasingly depends on matching the right mechanism to the right patient at the right stage of neuronal injury.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating neuroprotection research by improving target discovery, compound screening, imaging analytics, trial design, and patient monitoring. AI models can integrate genomics, proteomics, electronic health records, neuroimaging, and digital phenotyping to identify high-risk populations and biologically defined subgroups. This is especially relevant in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, stroke, traumatic brain injury, and retinal neurodegeneration, where disease heterogeneity has historically limited trial success.

The cumulative impact of AI is most visible in faster hypothesis generation and more efficient clinical development. Machine learning can detect subtle progression signals in MRI, PET, optical coherence tomography, speech, gait, and wearable sensor data, supporting earlier endpoint detection. However, industry adoption must be governed by explainability, bias mitigation, cybersecurity, validation across diverse populations, and compliance with evolving FDA, EMA, and data protection frameworks. AI will not replace clinical evidence, but it is becoming a critical infrastructure layer for precision neuroprotection.

Key Regional Insights Across Neuroprotection Markets

Asia-Pacific is one of the fastest-moving neuroprotection regions due to population aging, expanding stroke care, and high neuroscience investment in China, Japan, South Korea, India, and Australia. Japan’s super-aged population strengthens demand for dementia and Parkinson’s disease solutions, while China’s scale supports large patient cohorts and expanding clinical trial capacity. India’s burden of stroke, diabetes-related vascular risk, and traumatic injury is increasing the need for affordable neuroprotective and rehabilitation strategies.

North America remains a global leader in neuroprotection innovation, supported by NIH-funded neuroscience research, FDA regulatory pathways, advanced biomarker infrastructure, and deep clinical trial capacity. Europe benefits from strong public research networks, EMA oversight, rare disease and neuroscience programs, and coordinated health technology assessment, while Latin America shows growing demand linked to stroke, aging, and access expansion in Brazil and Mexico. The Middle East is investing in specialty hospitals, precision medicine, and tertiary neurology services, particularly in GCC markets, while Africa faces major access gaps but rising need due to stroke, infectious neurologic complications, epilepsy, and traumatic injury.

Key Group Insights for Strategic Market Prioritization

ASEAN markets are strengthening neuroprotection demand through expanding hospital networks, rising noncommunicable disease prevalence, and improving access to neurology services, although affordability and reimbursement variability remain key constraints. The GCC is investing in advanced tertiary care, genomics, and digital health, positioning the region for adoption of high-value neurodiagnostics and specialty neuroprotective therapies.

The European Union provides a structured environment for neuroscience research, clinical trials, pharmacovigilance, data protection, and health technology assessment, making evidence quality central to market access. BRICS countries combine large patient populations with expanding domestic manufacturing and clinical research capacity, creating scale opportunities for both innovative and cost-effective therapies. G7 markets remain the primary centers for premium neuroprotection innovation, regulatory science, advanced imaging, and specialist care, while NATO countries’ interest in traumatic brain injury, blast exposure, and military neurology supports specialized research into acute neuroprotection and rehabilitation.

Key Country Insights in Neuroprotection

The United States leads in neuroprotection research commercialization, with strong NIH funding, FDA precedent in neurodegenerative therapies, and high adoption of advanced diagnostics. Canada combines public healthcare access with neuroscience research strength, while Mexico and Brazil represent important Latin American markets where stroke care expansion and private-sector neurology demand are growing. The United Kingdom, Germany, France, Italy, and Spain support robust clinical research and reimbursement scrutiny, with Germany and France especially influential in health technology assessment and specialist care pathways.

Russia maintains neuroscience capabilities but faces geopolitical and access constraints that affect international collaboration. China is rapidly scaling neurology research, domestic biopharma, and clinical trial enrollment, while India offers large unmet need and cost-sensitive opportunities in stroke, epilepsy-related injury, and neurodegeneration. Japan’s aging population makes dementia and Parkinson’s disease priorities, South Korea is strong in digital health and biotechnology, and Australia contributes high-quality clinical research, registries, and regional trial leadership.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development strategies that define target populations, mechanism of action, and measurable neuroprotective outcomes before late-stage trials. Partnerships with academic neuroscience centers, imaging networks, clinical research organizations, and patient registries can improve recruitment quality and reduce endpoint uncertainty. Organizations should also design evidence packages that address regulators, payers, physicians, and caregivers, particularly where therapies are expensive, invasive, or require long-term monitoring.

Commercial leaders should segment opportunities by disease stage, care setting, and urgency of intervention. Acute indications such as stroke and traumatic brain injury require rapid administration models, emergency workflow alignment, and hospital protocol integration, while chronic diseases such as Alzheimer’s and Parkinson’s demand longitudinal evidence, adherence support, caregiver engagement, and safety monitoring. Scalable AI, real-world evidence, and decentralized assessment tools should be adopted, but only after validation in diverse populations and alignment with privacy and clinical governance standards.

Research Methodology

Research methodology is based on secondary research from verified public health, regulatory, clinical, and scientific sources, including the World Health Organization, national health agencies, peer-reviewed neuroscience literature, and publicly available regulatory information from authorities such as the FDA and EMA. The analysis evaluates disease burden, clinical development trends, technology adoption, regional healthcare capacity, and policy factors influencing the neuroprotection market.

The methodology emphasizes triangulation of evidence rather than reliance on single-source estimates. Insights are synthesized across epidemiology, clinical trial activity, biomarker adoption, reimbursement considerations, and healthcare infrastructure. Market interpretation excludes unsupported claims and focuses on data-backed drivers such as aging demographics, neurological disease prevalence, validated diagnostic advances, regulatory milestones, and documented artificial intelligence applications in neuroscience.

Conclusion

Neuroprotection is entering a more disciplined and commercially relevant phase, driven by aging populations, improved biomarkers, advanced imaging, AI-enabled discovery, and stronger understanding of neuronal injury mechanisms. The market opportunity is significant, but success will depend on clinical specificity, evidence quality, and the ability to demonstrate measurable preservation of neurological function.

Organizations that integrate precision medicine, regulatory-grade data, real-world monitoring, and region-specific access strategies will be best positioned to lead. As healthcare systems face growing neurological disease burden, neuroprotective therapies and technologies that deliver clinically meaningful outcomes can become central to the future of brain health, stroke recovery, and neurodegenerative disease management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neuroprotection Market, by Product Type
7.1. Introduction
7.2. Biologics
7.2.1. Monoclonal Antibody Biologics
7.2.2. Neurotrophic Factor Biologics
7.3. Drugs
7.3.1. Peptide Drugs
7.3.2. Small Molecule Drugs
7.4. Gene Therapy
7.5. Nutraceuticals
7.5.1. Herbal Extract Nutraceuticals
7.5.2. Mineral Nutraceuticals
7.5.3. Vitamin Nutraceuticals
7.6. Stem Cell Therapy
8. Neuroprotection Market, by Mechanism Of Action
8.1. Introduction
8.2. Anti Inflammatory Agents
8.2.1. Cytokine Inhibitor Anti Inflammatory Agents
8.2.2. NSAID Anti Inflammatory Agents
8.2.3. Steroid Anti Inflammatory Agents
8.3. Antioxidants
8.3.1. Flavonoid Antioxidants
8.3.2. Vitamin C Antioxidants
8.3.3. Vitamin E Antioxidants
8.4. Calcium Channel Blockers
8.4.1. Flunarizine Calcium Channel Blockers
8.4.2. Nimodipine Calcium Channel Blockers
8.5. Glutamate Inhibitors
8.6. Neurotrophic Factors
8.7. NMDA Antagonists
8.7.1. Ketamine NMDA Antagonists
8.7.2. Memantine NMDA Antagonists
9. Neuroprotection Market, by Indication
9.1. Introduction
9.2. Alzheimer's Disease
9.2.1. Early Stage Alzheimer's Disease
9.2.2. Moderate Stage Alzheimer's Disease
9.2.3. Severe Stage Alzheimer's Disease
9.3. Multiple Sclerosis
9.3.1. Relapsing Remitting Multiple Sclerosis
9.3.2. Secondary Progressive Multiple Sclerosis
9.4. Parkinson's Disease
9.4.1. Postural Instability Parkinson's Disease
9.4.2. Tremor Dominant Parkinson's Disease
9.5. Spinal Cord Injury
9.6. Stroke
9.6.1. Hemorrhagic Stroke
9.6.2. Ischemic Stroke
9.7. Traumatic Brain Injury
10. Neuroprotection Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Neuroprotection Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Healthcare
11.4. Hospitals
11.5. Research Institutes
12. Neuroprotection Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Neuroprotection Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Neuroprotection Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. AbbVie Inc.
16.3. AC Immune SA
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. BioArctic AB
16.7. Biogen Inc.
16.8. Bioniz Therapeutics Inc.
16.9. Boston Scientific Corporation
16.10. Denali Therapeutics Inc.
16.11. Eisai Co., Ltd.
16.12. Eli Lilly and Company
16.13. Genervon Biopharmaceuticals, LLC
16.14. GlaxoSmithKline plc
16.15. H. Lundbeck A/S
16.16. Hikma Pharmaceuticals PLC
16.17. Ipsen S.A.
16.18. Johnson & Johnson
16.19. LivaNova PLC
16.20. Medtronic plc
16.21. Merck & Co., Inc.
16.22. Neuren Pharmaceuticals Limited
16.23. Novartis AG
16.24. Pfizer Inc.
16.25. Roche Holding AG
16.26. Sanofi S.A.
16.27. Stryker Corporation
16.28. Sun Pharmaceutical Industries Limited
16.29. Teva Pharmaceutical Industries Ltd.
16.30. UCB S.A.
List of Figures
FIGURE 1. GLOBAL NEUROPROTECTION MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEUROPROTECTION MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEUROPROTECTION MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEUROPROTECTION MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEUROPROTECTION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MONOCLONAL ANTIBODY BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MONOCLONAL ANTIBODY BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODY BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NEUROTROPHIC FACTOR BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NEUROTROPHIC FACTOR BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NEUROTROPHIC FACTOR BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL HERBAL EXTRACT NUTRACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL HERBAL EXTRACT NUTRACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL HERBAL EXTRACT NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MINERAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MINERAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MINERAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL VITAMIN NUTRACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL VITAMIN NUTRACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL VITAMIN NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NSAID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NSAID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NSAID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL STEROID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL STEROID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL STEROID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIOXIDANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIOXIDANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL FLAVONOID ANTIOXIDANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL FLAVONOID ANTIOXIDANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL FLAVONOID ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL VITAMIN C ANTIOXIDANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL VITAMIN C ANTIOXIDANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL VITAMIN C ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL VITAMIN E ANTIOXIDANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL VITAMIN E ANTIOXIDANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL VITAMIN E ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL FLUNARIZINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL FLUNARIZINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL FLUNARIZINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NIMODIPINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NIMODIPINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NIMODIPINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GLUTAMATE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GLUTAMATE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL GLUTAMATE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL NEUROTROPHIC FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL NEUROTROPHIC FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL NEUROTROPHIC FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL KETAMINE NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL KETAMINE NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL KETAMINE NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL MEMANTINE NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MEMANTINE NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MEMANTINE NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL EARLY STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL EARLY STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL EARLY STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL MODERATE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MODERATE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL MODERATE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SEVERE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SEVERE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SEVERE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RELAPSING REMITTING MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RELAPSING REMITTING MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RELAPSING REMITTING MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL POSTURAL INSTABILITY PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL POSTURAL INSTABILITY PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL POSTURAL INSTABILITY PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL TREMOR DOMINANT PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL TREMOR DOMINANT PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL TREMOR DOMINANT PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL STROKE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL STROKE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL STROKE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL HEMORRHAGIC STROKE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL HEMORRHAGIC STROKE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL HEMORRHAGIC STROKE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL ISCHEMIC STROKE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ISCHEMIC STROKE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ISCHEMIC STROKE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. EUROPE NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. EUROPE NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 178. EUROPE NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 179. EUROPE NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 180. EUROPE NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 181. EUROPE NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 182. EUROPE NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 183. EUROPE NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 184. EUROPE NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 185. EUROPE NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 186. EUROPE NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 187. EUROPE NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 188. EUROPE NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 189. EUROPE NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 190. EUROPE NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 191. EUROPE NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. EUROPE NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 207. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 208. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 224. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 225. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. AFRICA NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 228. AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. AFRICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 230. AFRICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 231. AFRICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 232. AFRICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 233. AFRICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 234. AFRICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 235. AFRICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 236. AFRICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 237. AFRICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 238. AFRICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 239. AFRICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 240. AFRICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 241. AFRICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 242. AFRICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. AFRICA NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 259. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 260. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 262. NATO NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 263. NATO NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 264. NATO NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 265. NATO NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 266. NATO NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 267. NATO NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 268. NATO NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 269. NATO NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 270. NATO NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 271. NATO NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 272. NATO NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 273. NATO NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 274. NATO NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 275. NATO NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 276. NATO NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 277. NATO NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. NATO NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. G7 NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 280. G7 NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 281. G7 NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 282. G7 NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 283. G7 NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 284. G7 NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 285. G7 NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 286. G7 NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 287. G7 NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 288. G7 NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 289. G7 NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 290. G7 NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 291. G7 NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 292. G7 NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 293. G7 NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 294. G7 NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. G7 NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. BRICS NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 297. BRICS NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. BRICS NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 299. BRICS NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 300. BRICS NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 301. BRICS NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 302. BRICS NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 303. BRICS NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 304. BRICS NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 305. BRICS NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 306. BRICS NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 307. BRICS NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 308. BRICS NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 309. BRICS NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 310. BRICS NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 311. BRICS NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. BRICS NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 325. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 326. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 327. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 328. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 329. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 330. ASEAN NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 331. ASEAN NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 332. ASEAN NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 333. ASEAN NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 334. ASEAN NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 335. ASEAN NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 336. ASEAN NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 337. ASEAN NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 338. ASEAN NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 339. ASEAN NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 340. ASEAN NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 341. ASEAN NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 342. ASEAN NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 343. ASEAN NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 344. ASEAN NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 345. ASEAN NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 346. ASEAN NEUROPROTECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 347. GCC NEUROPROTECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 348. GCC NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 349. GCC NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 350. GCC NEUROPROTECTION MARKET SIZE, BY DRUGS, 2017-2032 (USD MILLION)
TABLE 351. GCC NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 352. GCC NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 353. GCC NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2017-2032 (USD MILLION)
TABLE 354. GCC NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2017-2032 (USD MILLION)
TABLE 355. GCC NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2017-2032 (USD MILLION)
TABLE 356. GCC NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2017-2032 (USD MILLION)
TABLE 357. GCC NEUROPROTECTION MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 358. GCC NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2017-2032 (USD MILLION)
TABLE 359. GCC NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2017-2032 (USD MILLION)
TABLE 360. GCC NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2017-2032 (USD MILLION)
TABLE 361. GCC NEUROPROTECTION MARKET SIZE, BY STROKE, 2017-2032 (USD MILLION)
TABLE 362. GCC NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 363. GCC NEUROPROTECTION MARKET

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • AC Immune SA
  • AstraZeneca PLC
  • Bayer AG
  • BioArctic AB
  • Biogen Inc.
  • Bioniz Therapeutics Inc.
  • Boston Scientific Corporation
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genervon Biopharmaceuticals, LLC
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Ipsen S.A.
  • Johnson & Johnson
  • LivaNova PLC
  • Medtronic plc
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Stryker Corporation
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 37.01 Billion
Forecasted Market Value ( USD ) by 2032 $ 58.74 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Neuroprotection Therapeutics - Global Strategic Business Report - Product Image

Neuroprotection Therapeutics - Global Strategic Business Report

  • Report
  • 236 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Neuroprotection Market Outlook 2026-2034: Market Share and Growth Analysis - Product Image

Neuroprotection Market Outlook 2026-2034: Market Share and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2 - Product Image

Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2

  • Book
  • Global
Portable IONM System Market - Global Forecast 2026-2032 - Product Image

Portable IONM System Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From

About the Neuroprotection Market

The Neuroprotection market within the context of Neurology Devices is focused on the development of products that protect the brain from damage caused by stroke, traumatic brain injury, and other neurological disorders. These products are designed to reduce the risk of long-term neurological damage and improve patient outcomes. Neuroprotection products include drugs, medical devices, and other therapies that can be used to reduce the risk of neurological damage. These products are used to reduce the risk of stroke, traumatic brain injury, and other neurological disorders. The Neuroprotection market is a rapidly growing segment of the Neurology Devices market, with a focus on improving patient outcomes and reducing the risk of long-term neurological damage. Companies in this market include Medtronic, Abbott, Boston Scientific, Stryker, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.